RespireRx Pharmaceuticals Inc (CE) (RSPI) ニュース

Exactly.

The ingredients and signs all point to this being something extremely special.

GLTU and all investors here.

The website under the CEO's profile says those funds are inactive and I am fairly certain CX929 no longer has any patent rights to it.

The 2 biggest news items that prefaced the move to the EM was the DOD funding phase 2 for SCI AND KRM-ll-81 progressing to tier 3 preclinicals which the CEO at this point suggested the drug was "remarkable" and NIH is finding out everything they have been saying that it works for pain and epilepsy. and they were working to open "purse strings". I don't think it is more complex than that. They even stated they want to position these assets for license, partnership or sale.

Most logical is that there is some deal in the works to take these assets deep into the human clinical realm.. And with that significant re-adjustment of market valuation here in order to capitalize on success and leverage the ability to move forward on 3 different promising platforms.

As I stated earlier, this has every indication of an NDA. Usual mode of operation of big Pharma.

We just wait and see while holding all shares very tightly.

Best of luck to all the faithful!

Cat

There are clues as to what is going on, I have made a career at event reconstruction which means I frequently take clues to an event and weigh differently than others. I am usually right, but sometimes wrong, usually due to missed or undisclosed evidence. With that said, the names of Lippa's and Margolis' venture capital funds are, "Atypical BioCapital Management LLC and Atypical BioVentures Fund LLC ". Hmmmm, now what do these funds do that aren't typical and how does it relate to RSPI? Now if you look at Lippa's history, he not only makes extraordinary investment calls in biotech, but also is involved in venture capital. Dare I call him the Warren Buffet of biotech? Now I go back to that PhD thesis where the author complained he could not publish his thesis until 2026. Could that mean CX929 is/will be an addition to RSPI's platform, and more importantly RSPI won't emerge from EM until 2026? I was anticipating emergence from EM this month or perhaps in February. Could it be we will have a really long wait? I sure won't be selling my shares until resolution (no pun intended)!

I agree. How many penny stocks have you ever seen that has government funding a phase 2 clinical trial AND another in a government funded preclinical program where all indications are it has been highly successful AND then the penny stock suddenly went quiet when BOD and execs have a history of ample capacity to support the company to keep filings up to date? Indicative.

If the NIH has been testing KRM-ll-81 in all kinds of tier 3 level preclinical pain models.... AND it is showing to be successful, you can absolutely bet the NIH wants to see this get into clinical trials ASAP and may even support various trials for pain management on top of trials for epilepsy. What would a significantly improved solution to opioids be worth?

Typical of pharma, I too expect things to unfold fast once they begin to engage the investment community.

Thank You, I was definitely being really conservative. I believe your numbers will most likely unfold here! I appreciate all of your input on this. We are looking at a potential life changing stock here! I am so glad I bought and held RSPI before it went to the expert market because when it comes off it will be really difficult to get any sizeable position for under .02 cents in my opinion. Once things start to move in the right direction, I believe it will really move fast.

Agree.

And .024 is a whopping 24 million market cap. 0.24 might be more plausible as these platforms get into clinical trials. Especially the phase 2 DOD SCI and phase 1 epilepsy trials for KRM-ll-81...

Curiously, there hasnt been any consultant agreement or discussion about getting KRM-ll-81 into trials for pain management with grant funding which is what the NIH preclinicals were all about in the first place... One would think they would have someone already lined up to assist in handling grant funding/trials for pain coming out of preclinicals.... One would think NIH would desire that to see their top tier 3 preclinical drugs get into human clinical trials ASAP.... hmmmm..

I definitely understand your frustration as we all pretty much can't believe they would go this route. I am sure there was a reason for them to take this route. With that said if they get a partnership, or a major investor to get one of these drugs across the finish line everything rapidly changes here.

Lippa stands to make probably the most money here off of these shares, so it will be in his best interest to move us forward.
Filings can easily be caught up so I am not worried on how many they may have to file once they decide to bring us current.
Big money has a way of making things move regardless of how difficult.

Sadly as more time goes by very doubtful. How many filings will they have to catch up on? This really is inexcusable as well as the company saying nothing about going current.

Love the Green and Can't wait for when it's for Real! However when that happens instead of .0024 we will probably be sitting at .024 which will be really nice!

buy now







capital loss later

Well that is what they claimed in the SEC filing about going to the EM. One could speculate that there should have been plenty of time and connections to cobble together something (maybe that is what the BOD loan was originally for) to stay current with filings.

They basically need a larger infusion of capital. If you look at the consultant agreement, the fees and such, they need probably $300k or more (guessing) to support that clinical. Then of course SCI phase 2 is coming up whenever and not sure if money or what is holding up OSA program. They need to support these platforms into clinicals and maybe more importantly prepare for the next step assuming success in any of these clinical trials. Thats why I think many speculate a bigger funding source or BP/JV type partner is potentially in the works as it makes a ton of sense and their filings have indicated as much about license, JV or sell assets!

"in the process of attempting to raise funds" I don't believe it. But all speculation on our part.

This thought has been on the back of my mind as well..

You mentioned it kinda felt they were waiting on a few more items... Maybe capital is lined up and just waiting for them to kick off the phase 2 SCI and/or the phase 1/2 dronabinol trials that the VA/UIC are collaborating on... Or possibly also what level of grant funding they can achieve for KRM-ll-81 can determine value in any deal. What is curious to me is that they hired consultants to apply for grants for the epilepsy indication.... yet the robust NIH preclincal efforts were sponsored with the intent of finding candidates for pain/opioid mitigation. I would think they would have grants lined up for this indication as well, or maybe NIH is helping coordinate next steps with a potential larger partner for the pain indication.... Maybe this quiet period is vetting out various levels of capital partners?

The only thing that is clear from the filings is that management has provided funding and has significant equity positions in this company whether shares or warrants or preferred.

"To cure the deficiency, the Company is in the process of attempting to raise funds of which no assurance can be provided". This is logical and has been continually referenced in filings as to the need for support capital as well as the goal to open "purse strings" to support KRM-ll-81. Given that they have essentially gone radio silent on communication and presentation for almost 8 months, that is highly suggestive of something like an NDA or negotiation period of some sort in play. Extremely frustrating for simple retail investors like those of us on this forum....

As pointed out here, with such successful endeavors in the past for many execs and BOD of RSPI, surely locating capital to keep the filings current especially with government funding would have been a slam dunk. Heck one BOD member supplied 100k loan right before filings due. They chose to "pause" the filing process as the claim was they are "in the process of attempting to raise funds"...

You are saying that the Officers of RSPI failed to file their required SEC reporting in order to enter the Expert Market with the intent of driving the share price down to where they could buy more, albeit indirectly, and thereby personally benefit.

Do you really think that's legal?

Ok. We know that Lippa and Margolis are principals in venturer capital firms. Googled AI noted: "A venture capital firm can partner with a publicly traded company by buying shares on the open market, becoming a significant shareholder ..." It appears the shares of RSPI owned by Atypical BioCapital Management LLC and Atypical BioVentures Fund LLC are not subject to public disclosure, so the actual float, excluding these venture capital firms holdings could be much smaller than it would suggest. If true, I have no idea where we shareholders stand in this apparently rare situation. But one thing apparent to me is that Lippa and Margolis have decided EM status somehow facilitates this arrangement just by allowing resources being directed elsewhere. But Margolis answers inquiries, albeit not to our satisfaction - at least we are not being completely ignored.

Well, I think the ampakines are well established history with high-impact causing toxicity issues that need overcome in order to advance those. Hence why I believe RSPI focused on soley the low impact ampakines CX1739 and CX717. Maybe longer term vision would be to advance a technology to revive the high impact ampakines and certainly there would have to be new patents to revive it, none of which is out there yet. And the dronabinol program is also well historied and apparently stagnant currently.

So, IMO, I think the commentary from the CEO about KRM-ll-81 is extremely genuine and the desire to open "purse strings" to support a "remarkable" drug could likely be the source for the silence and move to EM. The potential alone with grant funding for epilepsy is company making, but really would like to hear how the NIH preclinicals on pain observed the drug versus standard of care. The gravity of a possible leap in pain management away from opioids is well, astonishing...

We'll see where this all goes, but finding funding sources (considering the accomplishments of BOD, execs and collaborators) to complete simple SEC filings/responsibility should not have been a reason to "pause"... And to continue to drag this on now.... The picture must be much much bigger....

https://www.sciencedirect.com/science/article/pii/S002839082400279X

Well, LT, it is apparent that RSPI went into EM not based on financial insolvency. No bankruptcy filings occurred. It is my guess that Lippa and Margolis were intent on increasing their RSPI holdings through their venture capital firms and attracting capital to keep RSPI solvent with a platform unparalleled by any other small cap biotech (my opinion). As a scientist I am astounded at the worldwide research in ampakines as evidenced by the massive number of citations of the early (1990 to 2005) published work. RSPI made available their ampakines at a low price and then reaped the benefits of the preclinical research through the resulting published research. I have no doubt that strings were attached to access these compounds by university research groups. Was RSPI funding a likely very expensive manufacturing process to make their molecules available to university researchers?. In that regard that PhD thesis on CX929 the author complained that he could not publish those results until 2026. And Margolis wasn't aware of that thesis, which appears to now be unavailable on the internet?. And then we have dronabinol and KRM-II-81! May we all live long and prosper!

That is a great point. Clearly some executives and BOD are well off with past participation in equities or companies/endeavors they were connected. And these same individuals have provided funding and support for RSPI for years..

So just when they land a huge DOD funding phase 2 news AND just when another compound is looking superior for epilepsy and pain management in preclinicals..

Just when these assets on 3 platforms have never been better positioned, suddenly cannot find a little cash to complete simple filings???

what is it that the ceo trying to achieve by intentionally having gone to EM status?

"I suspect RSPI is not cash starved"

$6,362 as of 9/30/23 (most recent data....https://www.sec.gov/ix?doc=/Archives/edgar/data/0000849636/000149315223041875/form10-q.htm).
That's cash starved.

It would have to be some sort of merger.. but certainly plausible.

If they got the GOODS anything is possible, meanwhile we wait and see

I really do not understand the nuances of the markets, but could it be that RSPI is heading towards a NASDAQ listing?

No problem , i was just asking was that from 2019

The point is that Lippa likely was a substantial beneficiary of that sale.

Thats from the deal in 2019 correct

Lippa's DOV Pharmaceuticals:

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced a definitive agreement to acquire Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) by means of a tender offer. The consideration consists of an upfront payment of USD 27.50 per share in cash ...

Hang on folks, I suspect we are in for quite a ride.

Obviously we have a financial web concerning RSPI that is not on the books. Hmmm.... could one or more of these private funds be holding substantial amounts of RSPI stocks?

Mr. Margolis and Dr. Lippa founded and jointly managed, since 2004, Atypical BioCapital Management LLC and Atypical BioVentures Fund LLC,

Arnold S. Lippa was the founder of Patch International, Inc. (founded in 1984) where he held the title of President & Chief Operating Officer from 1984 to 1994. He was also the founder of DOV Pharmaceutical, Inc. (founded in 1995) where he served as a Director from 2005 to 2006. He is the founder of T.Morgen Capital LLC (founded in 2005) where he currently holds the title of Senior Managing Director. Furthermore, he is the founder of Xintria Pharmaceutical Corp. (founded in 2006) where he currently serves as the Executive Chairman. Lastly, he is the founder of Atypical BioCapital Management LLC (founded in 2004) where he currently holds the title of Manager.

Dr. Lippa's current job(s) include being the Executive Chairman, President & CEO at RespireRx Pharmaceuticals, Inc. since 2013 and the President of Aurora Capital LLC since 2005.

Dr. Lippa's former job(s) include being a Director-Molecular Neurobiology at Wyeth Holdings LLC, an Independent Director at Hepion Pharmaceuticals, Inc. from 2015 to 2023, and a Professor at City University of New York and New York University School of Medicine.

I suspect RSPI is not cash starved

It is too hard to predict exactly how this would trade.

Depends on if back on the OTC or are they possibly looking at some M&A to get off the OTC and on a more institutional exchange like NASDAQ? Without any filings we dont know where fully diluted status could be either. I roughly thought around 1.5 billion shares, but could be more with any additional small financings, could be less if the convertibles are somehow bought out in whatever structure the assets land in.

Supposedly the OSA program is independently valued at 20+ million and possibly "multiples" of that. We can speculate what a phase 2 SCI drug is worth, especially with DOD funding the clinical. As well as what KRM-ll-81 could be worth at phase1 stage for epilepsy, and possibly pain indications as well especially with grant funding. For a stock like this with 3 platforms at clinical stage with really a robust history of preclinical and clinical efforts, well IMO these are very valuable now heading into clincals. 3 pennies, 5 or 10+ pennies all plausible. I think the bigger valuation leap comes in 2026-2027 as results of clinical efforts come in and obviously need to be positive results. I'll keep a majority of my stack for that risk v reward scenario.

One woud have to assume that they understand the potential lost opportunities from collaborations and resources and impact of time erosion on assets with a non-chalant do nothing time period. Frustrating as an investor.

Id say id we get back on the market we open above 01 fomo will drive us close to 03 then fall back to 02 or a lil below and start our raise to a nickle and above once further updates and deals are posted as confirmed 

Going to be tough for the FOMO crowd as they generally can’t buy on EM unless Canadian account I guess.

By the time this trades with liquidity either on OTC or another exchange, the market might have this valuation corrected to a more reasonable level considering multiple platforms in clinicals…

I mean if the SCI trial is successful, value significantly increases as that will likely lead into ADHD trials. But if KRM-ll-81 is successful in phase 1, that will exponentially leap valuations as both epilepsy and pain/opioid mitigation are Huge markets needing better solutions.. Certainly BP has been looking at this neuromodulator platform. Could be huge assets to develop for a BP.

So building out resources and investor base would help smoothly transition the clinical phases which adds value!! Delay and dragging feet deplete value! Financial strength and flexibility adds significant value as well for obvious reasons.

Short term this has massive ROI potential just getting back on track, but longer term 2026-2027 clinical trial success can yield beyond imagination.. IMO

I am sure investors and all stakeholders alike are not looking for excuses and explanations. It is only logical and the significant progress/position of their platforms and the CEO comments about opening "purse strings" and all their commentary in past filings... logical that they went silent to get their house in order and that includes handling the debt, structuring the assets and negotiating with funding sources including BP.

As Catpole suggests, quite possibly there is an NDA or some type of silence agreement in play. At this point that is a logical assumption and a very good thing for shareholders as when they come out of this there is likely to be funding and resources in place to take these assets from say 50-100 million valuation to 5x that upon success in any of the upcoming clinical trials.

Yet this move to the expert market, dancing around filing responsibilites, lack of any updates and proper communication and presentation, etc, etc... well they should know by now what investors and stakeholders think of that strategy... Get this train on the rails and lets see these drugs flourish in clinicals!!

When communicating with Jeff CEO and Paul from the investor agent , My point blank question was if they were investors looking would they invest in RSPI based on the last 6 months and the actions they have showed is it a good look. No replie on answering it directly but both noted it is a concern they hope to explain and direction forward in the letter
IMO I think they are waiting on a few more goals and positive reults and then we see what this company will be going forward.
Stay safe for all that are in the weather storm forecast for the next couple of days , and positive thoughts for the fire victims GLTA

macroaxis.com:

"The fear of missing out, i.e., FOMO, can cause potential investors in RespireRX Pharmaceuticals to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying RespireRX because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money."

I can’t imagine them dragging their feet too much longer.. at this pace the patents will expire and new technology will trump in long before the insiders get any ROI on their loans or equity stakes, let alone payment events that unlock preferred or get any investment money back…

The stock has long ago consolidated into true long investor hands, not otc fanatics… lol. So get on with the show! Time erodes..

But it will be interesting if a letter emerges. There should have been one the next day after moving to the EM!!

You bring up a good point though with your pharma comparison. Most pharmas trade at high expectant valuations before and during clinicals, only to have failure drop it like a rock. RSPI is starting at rock bottom, Before heading into multiple clinical trials… with zero effort to address valuation. Shall we conclude they got the goods!!! Rock to Rocket!!

Yes look at this one , over the past 1 year. flying high then a bad result . SYRS Syros Pharmaceuticals Inc , I think the right results and news we could see SP in the dollars. This company doesnt have what we have been told RSPI has at look at their SP even today. Jeff was saying he was getting there , and was trying to explain everything good bad and what they have challeging left to get over and gives us what they want to get done in 2025. Hopefully they do have BP lined up and maybe it is a Buyout and the main players are kept on and running the show. Who knows GLTA

Remember how many times we thought the same thing over a 4 year span in ENZC?

UIC and the VA (sponsor) are collaborating on a phase 1/2 dronabinol trial in a few months according to notes on clinical site. I wonder how this connects?

Agree. I suppose BP/institutional won’t deploy capital until ready to start clinical trials. I suppose to they are likely waiting on extent of grant funding for KRM-ll-81. Confirmation of clinical starting/additional grants will set the stage for infusion of capital/resources..

These pharma turn on a dime and can run like crazy over a few months..

"In particular, we were highly dependent on Timothy L. Jones, our CEO and President who resigned effective January 31, 2022, and are highly dependent on Arnold S. Lippa, Ph.D., Interim CEO and Interim President, since the resignation of Mr. Jones, who is our Chief Scientific Officer and Executive Chairman, and Jeff E. Margolis, our Senior Vice President, Chief Financial Officer, Treasurer and Secretary."

https://www.sec.gov/ix?doc=/Archives/edgar/data/0000849636/000149315222010053/form10-k.htm

Modified: March 21, 2022 at 9:34:39 PM EDT

I suspect we hear more as the trials either begin or continue. Many irons in the fire and should be of interest to big Pharma. My experience is that NDA' can be frustrating to investors as they remain in the dark until the NDA agreement ends. We can only hope that positive movement is being made, and communication comes as per Jeff, "near future". In the meantime, I just sit with my considerable number of shares and hope the lid is blown off very soon.
I have much interest in the potential treatment for pain as I have experience four joint replacements and multiple heart procedures. I hated coming off the addictive pain killers. I guess I could also state I have interest in potential sleep medication as I use a CPAP.

I have thought that from the get-go as it makes sense and it fits the logic of them not parlaying the DOD news and advancement in NIH preclinicals into significant investor interest that would have easily funded filings and thensome. Allowing this much time to now pass with zero communication and updates on anything or on the company presentation is a bit confirming in my mind. They likely have a plan in place for funding and supporting clinicals. Whether institutional investors or BP come aboard or all of the above who knows...

Excited to see the clinicals get going as it will open many doors for investors and patients needing treatments.

I sincerely hope that is the case otherwise this whole operation has been severely mismanaged